Grifols (GRFS) Competitors $7.02 +0.07 (+1.01%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$7.25 +0.23 (+3.22%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, and ROIVShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Grifols (NASDAQ:GRFS) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Which has more risk & volatility, GRFS or SMMT? Grifols has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Do institutionals & insiders believe in GRFS or SMMT? 4.6% of Summit Therapeutics shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor GRFS or SMMT? Grifols received 39 more outperform votes than Summit Therapeutics when rated by MarketBeat users. However, 58.57% of users gave Summit Therapeutics an outperform vote while only 56.09% of users gave Grifols an outperform vote. CompanyUnderperformOutperformGrifolsOutperform Votes35056.09% Underperform Votes27443.91% Summit TherapeuticsOutperform Votes31158.57% Underperform Votes22041.43% Does the media favor GRFS or SMMT? In the previous week, Summit Therapeutics had 21 more articles in the media than Grifols. MarketBeat recorded 27 mentions for Summit Therapeutics and 6 mentions for Grifols. Grifols' average media sentiment score of 1.36 beat Summit Therapeutics' score of 0.71 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GRFS or SMMT? Summit Therapeutics has a consensus target price of $37.50, indicating a potential upside of 52.01%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GRFS or SMMT more profitable? Grifols' return on equity of 0.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Summit Therapeutics N/A -85.42%-52.66% Which has better valuation & earnings, GRFS or SMMT? Grifols has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.21B0.67$64.20M$1.176.00Summit Therapeutics$700K25,997.95-$614.93M-$0.31-79.58 SummaryGrifols beats Summit Therapeutics on 11 of the 18 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.83B$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio6.007.3222.5118.54Price / Sales0.67241.49397.62103.30Price / Cash9.5465.8538.1834.62Price / Book0.566.486.734.25Net Income$64.20M$143.41M$3.22B$248.18M7 Day Performance-2.64%2.58%1.38%1.03%1 Month Performance-6.28%5.00%2.79%2.70%1 Year Performance9.86%-3.72%15.41%4.05% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.8996 of 5 stars$7.02+1.0%N/A+3.4%$4.83B$7.21B6.0026,300Short Interest ↓Positive NewsSMMTSummit Therapeutics2.6504 of 5 stars$25.22+2.5%$35.40+40.4%+424.9%$18.60B$700,000.00-90.07110Earnings ReportAnalyst RevisionPositive NewsTEVATeva Pharmaceutical Industries3.0952 of 5 stars$13.30-2.6%$23.43+76.2%+11.8%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsGap UpITCIIntra-Cellular Therapies0.8828 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4371 of 5 stars$20.07+0.1%$39.17+95.2%-27.2%$13.28B$21.53B11.531,660Upcoming EarningsPositive NewsRDYDr. Reddy's Laboratories1.8412 of 5 stars$13.68+0.1%$17.00+24.3%-6.5%$11.42B$311.31B21.7824,800Upcoming EarningsPositive NewsASNDAscendis Pharma A/S2.3081 of 5 stars$161.15-2.4%$204.67+27.0%+18.8%$9.83B$363.64M-22.70640News CoveragePositive NewsMRNAModerna4.3548 of 5 stars$25.13+1.7%$58.70+133.6%-75.7%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageGap DownVTRSViatris1.6837 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6842 of 5 stars$40.51-0.5%$47.83+18.1%+1.4%$9.01B$1.98B112.806,030Upcoming EarningsROIVRoivant Sciences2.1942 of 5 stars$10.04-1.1%$17.50+74.3%+3.3%$7.16B$122.59M-66.93860Positive News Related Companies and Tools Related Companies SMMT Alternatives TEVA Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ROIV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
